Skip to main content
Top
Published in: BMC Infectious Diseases 1/2021

Open Access 01-12-2021 | Cholera | Research

Three transmission events of Vibrio cholerae O1 into Lusaka, Zambia

Authors: John Mwaba, Amanda K. Debes, Kelsey N. Murt, Patrick Shea, Michelo Simuyandi, Natasha Laban, Katayi Kazimbaya, Caroline Chisenga, Shan Li, Mathieu Almeida, Jacquelyn S. Meisel, Aaron Shibemba, Timothy Kantenga, Victor Mukonka, Geoffrey Kwenda, David A. Sack, Roma Chilengi, O. Colin Stine

Published in: BMC Infectious Diseases | Issue 1/2021

Login to get access

Abstract

Background

Cholera has been present and recurring in Zambia since 1977. However, there is a paucity of data on genetic relatedness and diversity of the Vibrio cholerae isolates responsible for these outbreaks. Understanding whether the outbreaks are seeded from existing local isolates or if the outbreaks represent separate transmission events can inform public health decisions.

Results

Seventy-two V. cholerae isolates from outbreaks in 2009/2010, 2016, and 2017/2018 in Zambia were characterized using multilocus variable number tandem repeat analysis (MLVA) and whole genome sequencing (WGS). The isolates had eight distinct MLVA genotypes that clustered into three MLVA clonal complexes (CCs). Each CC contained isolates from only one outbreak. The results from WGS revealed both clustered and dispersed single nucleotide variants. The genetic relatedness of isolates based on WGS was consistent with the MLVA, each CC was a distinct genetic lineage and had nearest neighbors from other East African countries. In Lusaka, isolates from the same outbreak were more closely related to themselves and isolates from other countries than to isolates from other outbreaks in other years.

Conclusions

Our observations are consistent with i) the presence of random mutation and alternative mechanisms of nucleotide variation, and ii) three separate transmission events of V. cholerae into Lusaka, Zambia. We suggest that locally, case-area targeted invention strategies and regionally, well-coordinated plans be in place to effectively control future cholera outbreaks.
Appendix
Available only for authorised users
Literature
3.
go back to reference De R, Ghosh JB, Sen Gupta S, Takeda Y, Nair GB. The Role of Vibrio cholerae Genotyping in Africa. J Infect Dis. 2013;208(SUPPL. 1):532-8. De R, Ghosh JB, Sen Gupta S, Takeda Y, Nair GB. The Role of Vibrio cholerae Genotyping in Africa. J Infect Dis. 2013;208(SUPPL. 1):532-8.
5.
go back to reference Bénard AHM, Guenou E, Fookes M, Ateudjieu J, Kasambara W, Siever M, et al. Whole genome sequence of vibrio cholerae directly from dried spotted filter paper. PLoS Negl Trop Dis. 2019;13(5):e0007330. Bénard AHM, Guenou E, Fookes M, Ateudjieu J, Kasambara W, Siever M, et al. Whole genome sequence of vibrio cholerae directly from dried spotted filter paper. PLoS Negl Trop Dis. 2019;13(5):e0007330.
9.
go back to reference Chen S, Zhou Y, Chen Y, Gu J. Fastp: An ultra-fast all-in-one FASTQ preprocessor. In: Bioinformatics. Oxford University Press; 2018. p. i884–90. Chen S, Zhou Y, Chen Y, Gu J. Fastp: An ultra-fast all-in-one FASTQ preprocessor. In: Bioinformatics. Oxford University Press; 2018. p. i884–90.
15.
go back to reference Treangen TJ, Ondov BD, Koren S, Phillippy AM. The harvest suite for rapid core-genome alignment and visualization of thousands of intraspecific microbial genomes. Genome Biol. 2014;15(11):1–15.CrossRef Treangen TJ, Ondov BD, Koren S, Phillippy AM. The harvest suite for rapid core-genome alignment and visualization of thousands of intraspecific microbial genomes. Genome Biol. 2014;15(11):1–15.CrossRef
16.
go back to reference Price MN, Dehal PS, Arkin AP. FastTree 2 - approximately maximum-likelihood trees for large alignments. PLoS One. 2010;10, 5(3):e9490. Price MN, Dehal PS, Arkin AP. FastTree 2 - approximately maximum-likelihood trees for large alignments. PLoS One. 2010;10, 5(3):e9490.
21.
go back to reference Kachwamba Y, Mohammed AA, Lukupulo H, Urio L, Majigo M, Mosha F, et al. Genetic characterization of Vibrio cholerae O1 isolates from outbreaks between 2011 and 2015 in Tanzania. BMC Infect Dis. 2017;17(1):1–6.CrossRef Kachwamba Y, Mohammed AA, Lukupulo H, Urio L, Majigo M, Mosha F, et al. Genetic characterization of Vibrio cholerae O1 isolates from outbreaks between 2011 and 2015 in Tanzania. BMC Infect Dis. 2017;17(1):1–6.CrossRef
27.
go back to reference Michel E, Gaudart J, Beaulieu S, Bulit G, Piarroux M, Boncy J, et al. Full title: estimating effectiveness of case-area targeted response interventions against cholera in Haiti. Elife. 2019;1:8. Michel E, Gaudart J, Beaulieu S, Bulit G, Piarroux M, Boncy J, et al. Full title: estimating effectiveness of case-area targeted response interventions against cholera in Haiti. Elife. 2019;1:8.
Metadata
Title
Three transmission events of Vibrio cholerae O1 into Lusaka, Zambia
Authors
John Mwaba
Amanda K. Debes
Kelsey N. Murt
Patrick Shea
Michelo Simuyandi
Natasha Laban
Katayi Kazimbaya
Caroline Chisenga
Shan Li
Mathieu Almeida
Jacquelyn S. Meisel
Aaron Shibemba
Timothy Kantenga
Victor Mukonka
Geoffrey Kwenda
David A. Sack
Roma Chilengi
O. Colin Stine
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2021
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-021-06259-5

Other articles of this Issue 1/2021

BMC Infectious Diseases 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine